Published in J Clin Microbiol on February 01, 2004
Enzymatic incorporation of a third nucleobase pair. Nucleic Acids Res (2007) 1.79
Amplification, mutation, and sequencing of a six-letter synthetic genetic system. J Am Chem Soc (2011) 1.78
Evaluation of the COBAS Hepatitis C Virus (HCV) TaqMan analyte-specific reagent assay and comparison to the COBAS Amplicor HCV Monitor V2.0 and Versant HCV bDNA 3.0 assays. J Clin Microbiol (2005) 1.58
Multilaboratory comparison of hepatitis C virus viral load assays. J Clin Microbiol (2006) 1.53
A novel diagnostic target in the hepatitis C virus genome. PLoS Med (2009) 1.52
Comparison of conventional PCR with real-time PCR and branched DNA-based assays for hepatitis C virus RNA quantification and clinical significance for genotypes 1 to 5. J Clin Microbiol (2006) 1.49
The use of thymidine analogs to improve the replication of an extra DNA base pair: a synthetic biological system. Nucleic Acids Res (2005) 1.49
Expanded genetic alphabets in the polymerase chain reaction. Angew Chem Int Ed Engl (2010) 1.38
Artificially expanded genetic information system: a new base pair with an alternative hydrogen bonding pattern. Nucleic Acids Res (2006) 1.32
Health-related quality of life and impact of antiviral treatment in Chinese patients with chronic hepatitis C in Taiwan. World J Gastroenterol (2005) 1.07
Performance of the Abbott real-time PCR assay using m2000sp and m2000rt for hepatitis C virus RNA quantification. J Clin Microbiol (2009) 0.99
Transcriptional profiling of TLR-4/7/8-stimulated guinea pig splenocytes and whole blood by bDNA assay. J Immunol Methods (2011) 0.91
Conversion strategy using an expanded genetic alphabet to assay nucleic acids. Anal Chem (2013) 0.90
Design of a novel molecular beacon: modification of the stem with artificially genetic alphabet. Chem Commun (Camb) (2008) 0.84
Is HCV core antigen a reliable marker of viral load? An evaluation of HCV core antigen automated immunoassay. Ann Gastroenterol (2013) 0.81
DNA polymerases engineered by directed evolution to incorporate non-standard nucleotides. Front Microbiol (2014) 0.80
A man-made ATP-binding protein evolved independent of nature causes abnormal growth in bacterial cells. PLoS One (2009) 0.78
Sequence determination of nucleic acids containing 5-methylisocytosine and isoguanine: identification and insight into polymerase replication of the non-natural nucleobases. Nucleic Acids Res (2005) 0.77
Detecting respiratory viral RNA using expanded genetic alphabets and self-avoiding DNA. Anal Biochem (2015) 0.77
Analytical and biological variables influencing quantitative hepatitis C virus (HCV) measurement in HIV-HCV coinfection. Can J Gastroenterol (2006) 0.75
Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med (2002) 36.55
Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet (2001) 35.17
The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med (1999) 16.35
Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group. N Engl J Med (1998) 6.23
Peginterferon alfa-2a in patients with chronic hepatitis C. N Engl J Med (2000) 5.58
A branched DNA signal amplification assay for quantification of nucleic acid targets below 100 molecules/ml. Nucleic Acids Res (1997) 4.40
Hepatitis C: the clinical spectrum of disease. Hepatology (1997) 3.94
Is an "a la carte" combination interferon alfa-2b plus ribavirin regimen possible for the first line treatment in patients with chronic hepatitis C? The ALGOVIRC Project Group. Hepatology (2000) 3.42
Establishment of the first international standard for nucleic acid amplification technology (NAT) assays for HCV RNA. WHO Collaborative Study Group. Vox Sang (1999) 3.07
Accurate quantification of hepatitis C virus (HCV) RNA from all HCV genotypes by using branched-DNA technology. J Clin Microbiol (1996) 2.26
Use and interpretation of virological tests for hepatitis C. Hepatology (2002) 1.92
Appendix: The National Institutes of Health Consensus Development Conference Management of Hepatitis C 2002. Clin Liver Dis (2003) 1.76
Preparation and characterization of RNA standards for use in quantitative branched DNA hybridization assays. Anal Biochem (1995) 1.69
Standardization of hepatitis C virus RNA quantification. Hepatology (2000) 1.52
Therapy of hepatitis C: meta-analysis of interferon alfa-2b trials. Hepatology (1997) 1.51
Calibration of HCV working reagents for NAT assays against the HCV international standard. The Collaborative Study Group. Vox Sang (2000) 1.49
Prognostic factors and early predictability of sustained viral response with peginterferon alfa-2a (40KD). J Hepatol (2002) 1.43
Performance of the New Bayer VERSANT HCV RNA 3.0 assay for quantitation of hepatitis C virus RNA in plasma and serum: conversion to international units and comparison with the Roche COBAS Amplicor HCV Monitor, Version 2.0, assay. J Clin Microbiol (2002) 1.31
Quantitation of hepatitis C virus RNA by third generation branched DNA-based signal amplification assay. J Virol Methods (2002) 1.30
Comparative evaluation of the VERSANT HCV RNA 3.0, QUANTIPLEX HCV RNA 2.0, and COBAS AMPLICOR HCV MONITOR version 2.0 Assays for quantification of hepatitis C virus RNA in serum. J Clin Microbiol (2002) 1.15
Evaluation of the VERSANT HCV RNA 3.0 assay for quantification of hepatitis C virus RNA in serum. J Clin Microbiol (2002) 1.14
The clinical utility of viral quantitation using molecular methods. Clin Diagn Virol (1998) 1.06
Global cost modeling analysis of HIV-1 and HCV viral load assays. Expert Rev Pharmacoecon Outcomes Res (2003) 1.00
Comparison of methodologies for quantification of hepatitis C virus (HCV) RNA in patients coinfected with HCV and human immunodeficiency virus. Clin Infect Dis (2002) 0.89
Health care industries' perspective of viral load assays: the VERSANT HIV-1 RNA 3.0 assay. Expert Rev Mol Diagn (2002) 0.88
Telaprevir for previously treated chronic HCV infection. N Engl J Med (2010) 8.33
Cost-effectiveness of screening for HIV in the era of highly active antiretroviral therapy. N Engl J Med (2005) 7.98
Effect of home testing of international normalized ratio on clinical events. N Engl J Med (2010) 5.36
Peginterferon and ribavirin treatment in African American and Caucasian American patients with hepatitis C genotype 1. Gastroenterology (2006) 4.90
Burden of liver disease in the United States: summary of a workshop. Hepatology (2002) 4.00
Severe pneumonia due to adenovirus serotype 14: a new respiratory threat? Clin Infect Dis (2008) 3.10
An interferon-free antiviral regimen for HCV after liver transplantation. N Engl J Med (2014) 3.04
High levels of adherence do not prevent accumulation of HIV drug resistance mutations. AIDS (2003) 2.65
Serum sodium predicts mortality in patients listed for liver transplantation. Hepatology (2005) 2.63
Evidence-based incorporation of serum sodium concentration into MELD. Gastroenterology (2006) 2.62
siRNA delivery into human T cells and primary cells with carbon-nanotube transporters. Angew Chem Int Ed Engl (2007) 2.61
Estimation of warfarin maintenance dose based on VKORC1 (-1639 G>A) and CYP2C9 genotypes. Clin Chem (2007) 2.56
Polyclonal long-term repopulating stem cell clones in a primate model. Blood (2002) 2.53
The combination of ribavirin and peginterferon is superior to peginterferon and placebo for children and adolescents with chronic hepatitis C. Gastroenterology (2010) 2.48
Accuracy of the TRUGENE HIV-1 genotyping kit. J Clin Microbiol (2003) 2.32
Risk prediction of hepatocellular carcinoma in patients with cirrhosis: the ADRESS-HCC risk model. Cancer (2014) 2.26
Racial and ethnic distribution of nonalcoholic fatty liver in persons with newly diagnosed chronic liver disease. Hepatology (2005) 2.24
An international multicenter performance analysis of cytomegalovirus load tests. Clin Infect Dis (2012) 2.20
Ultrasensitive detection of rare mutations using next-generation targeted resequencing. Nucleic Acids Res (2011) 2.11
Violent behavior and hallucination in a 32-year-old patient. Clin Chem (2013) 2.02
New protease inhibitors for the treatment of chronic hepatitis C: a cost-effectiveness analysis. Ann Intern Med (2012) 1.96
Food, shelter and safety needs motivating homeless persons' visits to an urban emergency department. Ann Emerg Med (2008) 1.85
PHOENIX: A randomized controlled trial of peginterferon alfa-2a plus ribavirin as a prophylactic treatment after liver transplantation for hepatitis C virus. Liver Transpl (2011) 1.85
Proteomics: a new diagnostic frontier. Clin Chem (2006) 1.82
The critically ill child with novel H1N1 influenza A: a case series. Pediatr Crit Care Med (2010) 1.77
Verification of an assay for quantification of hepatitis C virus RNA by use of an analyte-specific reagent and two different extraction methods. J Clin Microbiol (2004) 1.74
Integrating tobacco cessation into mental health care for posttraumatic stress disorder: a randomized controlled trial. JAMA (2010) 1.71
Phylogeny of Zika Virus in Western Hemisphere, 2015. Emerg Infect Dis (2016) 1.68
Laboratory test results after living liver donation in the adult-to-adult living donor liver transplantation cohort study. Liver Transpl (2011) 1.59
HIV infection in the elderly. Clin Interv Aging (2008) 1.59
Multicenter evaluation of the Bayer VERSANT HIV-1 RNA 3.0 assay: analytical and clinical performance. J Clin Virol (2002) 1.58
Detection of cytomegalovirus DNA in plasma as an adjunct diagnostic for gastrointestinal tract disease in kidney and liver transplant recipients. Clin Infect Dis (2013) 1.57
Comparison of automated and manual nucleic acid extraction methods for detection of enterovirus RNA. J Clin Microbiol (2003) 1.56
Inhibition of HIV infectivity by a natural human isolate of Lactobacillus jensenii engineered to express functional two-domain CD4. Proc Natl Acad Sci U S A (2003) 1.56
Alcohol use and hepatitis C. Hepatology (2002) 1.55
Application of the hybrid capture 2 assay to squamous cell carcinomas of the head and neck: a convenient liquid-phase approach for the reliable determination of human papillomavirus status. Cancer Cytopathol (2011) 1.54
Recipient-donor race mismatch for African American liver transplant patients with chronic hepatitis C. Liver Transpl (2012) 1.54
Kidney and liver transplantation in human immunodeficiency virus-infected patients: a pilot safety and efficacy study. Transplantation (2003) 1.54
Hepatic steatosis at 1 year is an additional predictor of subsequent fibrosis severity in liver transplant recipients with recurrent hepatitis C virus. Liver Transpl (2011) 1.52
Dosing algorithm for warfarin using CYP2C9 and VKORC1 genotyping from a multi-ethnic population: comparison with other equations. Pharmacogenomics (2008) 1.50
Risk of cardiovascular disease from antiretroviral therapy for HIV: a systematic review. PLoS One (2013) 1.49
De novo biosynthesis and radiolabeling of mammalian digitalis-like factors. Clin Chem (2004) 1.43
Trends in waiting list registration for liver transplantation for viral hepatitis in the United States. Gastroenterology (2009) 1.35
Long-term clinical and molecular follow-up of large animals receiving retrovirally transduced stem and progenitor cells: no progression to clonal hematopoiesis or leukemia. Mol Ther (2004) 1.33
Outcomes of donor evaluation in adult-to-adult living donor liver transplantation. Hepatology (2007) 1.31
Specific human leukocyte antigen class I and II alleles associated with hepatitis C virus viremia. Hepatology (2010) 1.28
Warfarin dose adjustments based on CYP2C9 genetic polymorphisms. J Thromb Thrombolysis (2002) 1.27
Clinical accuracy of a PLEX-ID flu device for simultaneous detection and identification of influenza viruses A and B. J Clin Microbiol (2012) 1.25
Novel targets for antiretroviral therapy: clinical progress to date. Drugs (2009) 1.25
Reverse transcription polymerase chain reaction and electrospray ionization mass spectrometry for identifying acute viral upper respiratory tract infections. Diagn Microbiol Infect Dis (2011) 1.23
Cost-effectiveness of HIV screening in patients older than 55 years of age. Ann Intern Med (2008) 1.23
Rapid identification viruses from nasal pharyngeal aspirates in acute viral respiratory infections by RT-PCR and electrospray ionization mass spectrometry. J Virol Methods (2011) 1.22
A randomized controlled trial of pretransplant antiviral therapy to prevent recurrence of hepatitis C after liver transplantation. Hepatology (2013) 1.21
Impact of disease severity on healthcare costs in patients with chronic hepatitis C (CHC) virus infection. Hepatology (2012) 1.20
Effect of long-term highly active antiretroviral therapy in restoring HIV-induced abnormal B-lymphocyte function. J Acquir Immune Defic Syndr (2002) 1.19
Oseltamivir for treatment and prophylaxis of influenza infection. Expert Opin Drug Saf (2009) 1.19
Detecting respiratory viruses in asymptomatic children. Pediatr Infect Dis J (2012) 1.19
Quality of life of patients with advanced HIV/AIDS: measuring the impact of both AIDS-defining events and non-AIDS serious adverse events. J Acquir Immune Defic Syndr (2009) 1.19
The effect of diagnosis with HIV infection on health-related quality of Life. Qual Life Res (2006) 1.18
Limitations of conventionally derived chronic liver disease mortality rates: Results of a comprehensive assessment. Hepatology (2008) 1.17
Modulation of disease, T cell responses, and measles virus clearance in monkeys vaccinated with H-encoding alphavirus replicon particles. Proc Natl Acad Sci U S A (2005) 1.16
Prospective analysis of depression during peginterferon and ribavirin therapy of chronic hepatitis C: results of the Virahep-C study. Am J Gastroenterol (2009) 1.16
Multicenter evaluation of the VERSANT hepatitis B virus DNA 3.0 assay. J Clin Microbiol (2004) 1.15
Differential CMV-specific CD8+ effector T cell responses in the lung allograft predominate over the blood during human primary infection. J Immunol (2008) 1.15
Cost-effectiveness analysis of risk-factor guided and birth-cohort screening for chronic hepatitis C infection in the United States. PLoS One (2013) 1.14
Hospitalization rates before and after adult-to-adult living donor or deceased donor liver transplantation. Ann Surg (2010) 1.13
Necrotizing peripheral vasculitis/vasculopathy following the use of cocaine laced with levamisole. J Burn Care Res (2012) 1.12
Role of environmental surveillance in determining the risk of hospital-acquired legionellosis: a national surveillance study with clinical correlations. Infect Control Hosp Epidemiol (2007) 1.12
New onset diabetes mellitus after liver transplantation: the critical role of hepatitis C infection. Liver Transpl (2004) 1.11
The changing epidemiology and natural history of hepatitis C virus infection. Clin Liver Dis (2006) 1.11
Development of elvitegravir resistance and linkage of integrase inhibitor mutations with protease and reverse transcriptase resistance mutations. PLoS One (2012) 1.11
Prevalence of HIV infection among inpatients and outpatients in Department of Veterans Affairs health care systems: implications for screening programs for HIV. Am J Public Health (2007) 1.10
Safety of zoster vaccine in elderly adults following documented herpes zoster. J Infect Dis (2013) 1.09
Hepatitis C virus-infected women have a higher risk of advanced fibrosis and graft loss after liver transplantation than men. Hepatology (2011) 1.09
Influence of cannabis use on severity of hepatitis C disease. Clin Gastroenterol Hepatol (2008) 1.08
Diagnosing invasive fungal disease in critically ill patients. Crit Rev Microbiol (2011) 1.08
Applicability, tolerability and efficacy of preemptive antiviral therapy in hepatitis C-infected patients undergoing liver transplantation. Am J Transplant (2005) 1.06
Large animal models for stem and progenitor cell analysis. Curr Protoc Immunol (2005) 1.06
Simultaneous runs of the Bayer VERSANT HIV-1 version 3.0 and HCV bDNA version 3.0 quantitative assays on the system 340 platform provide reliable quantitation and improved work flow. J Clin Microbiol (2004) 1.06
Evaluation of an automated, highly sensitive, real-time PCR-based assay (COBAS Ampliprep/COBAS TaqMan) for quantification of HCV RNA. J Clin Virol (2008) 1.06
A systematic review of cost-utility analyses in HIV/AIDS: implications for public policy. Med Decis Making (2007) 1.05
Enhanced health event detection and influenza surveillance using a joint Veterans Affairs and Department of Defense biosurveillance application. BMC Med Inform Decis Mak (2011) 1.04
HIV testing of at risk patients in a large integrated health care system. J Gen Intern Med (2007) 1.03
Cost effectiveness of screening strategies for early identification of HIV and HCV infection in injection drug users. PLoS One (2012) 1.03
From personalized medicine to personalized justice: the promises of translational pharmacogenomics in the justice system. Pharmacogenomics (2010) 1.01
Treatment of hepatitis C in liver transplant patients: interferon out, direct antiviral combos in. Liver Transpl (2015) 1.01
Is spinal tuberculosis contagious? Int J Infect Dis (2010) 1.00
Bikunin (urinary trypsin inhibitor): structure, biological relevance, and measurement. Adv Clin Chem (2007) 1.00
Peginterferon pharmacokinetics in African American and Caucasian American patients with hepatitis C virus genotype 1 infection. Clin Gastroenterol Hepatol (2008) 1.00
Diagnostic performance of two highly multiplexed respiratory virus assays in a pediatric cohort. J Clin Virol (2012) 1.00
Management of hepatitis B in liver transplant recipients. J Viral Hepat (2007) 0.99
Sofosbuvir-based treatment regimens for chronic, genotype 1 hepatitis C virus infection in U.S. incarcerated populations: a cost-effectiveness analysis. Ann Intern Med (2014) 0.99
External financial aid to blood transfusion services in sub-Saharan Africa: a need for reflection. PLoS Med (2012) 0.98
One-year outcomes of community-acquired and healthcare-associated pneumonia in the Veterans Affairs Healthcare System. Int J Infect Dis (2011) 0.97
Health-related quality of life assessment after antiretroviral therapy: a review of the literature. Drugs (2013) 0.97
Respiratory syncytial virus detection by Remel Xpect, Binax Now RSV, direct immunofluorescent staining, and tissue culture. J Clin Microbiol (2006) 0.97